CAR-T & Cellular Immunotherapy

China leads the world in CAR-T research and access. It has approved seven commercial CAR-T products and runs the most CAR-T clinical trials globally. Patients who cannot access these therapies at home — or who face prohibitive costs — increasingly consider China, especially through the Boao Lecheng Pilot Zone's early-access policy and leading centers in Shanghai, Beijing, Guangzhou and Tianjin.

Key points

• 7 approved commercial products, mainly for blood cancers such as lymphoma and multiple myeloma
• Drug cost roughly $150,000–180,000 — about a third of typical US pricing; full treatment (drugs, hospital stay, procedure) often $180,000–220,000 vs $600,000+ in the US
• For those eligible, clinical-trial participation is sometimes possible at a fraction of the cost
• Eligibility screening, biomarker testing and case review arranged before travel

CAR-T is a specialized, hospital-based therapy with serious side-effect risks. Our team helps you evaluate eligibility, choose a center and plan follow-up care — we do not promise outcomes.